Abivax (NASDAQ:ABVX) Given New $145.00 Price Target at Morgan Stanley

Abivax (NASDAQ:ABVX) had its target price hoisted by Morgan Stanley from $101.00 to $145.00 in a research report report published on Friday morning, Marketbeat reports. They currently have an overweight rating on the stock.

ABVX has been the topic of several other reports. BTIG Research upped their price target on shares of Abivax from $120.00 to $150.00 and gave the company a “buy” rating in a report on Thursday. Guggenheim reaffirmed a “buy” rating and set a $175.00 price objective on shares of Abivax in a research note on Thursday, December 18th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Wolfe Research raised shares of Abivax to a “strong-buy” rating in a report on Thursday, November 6th. Finally, Barclays began coverage on shares of Abivax in a research report on Monday, October 13th. They set an “overweight” rating and a $142.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $135.08.

Abivax Price Performance

Shares of NASDAQ:ABVX opened at $114.40 on Friday. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a market cap of $8.92 billion, a PE ratio of -27.37 and a beta of 0.68. The company’s 50 day moving average is $120.17 and its 200 day moving average is $84.55.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The business had revenue of ($4.92) million for the quarter. On average, sell-side analysts forecast that Abivax will post -2.83 EPS for the current year.

Institutional Investors Weigh In On Abivax

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kennedy Capital Management LLC increased its stake in shares of Abivax by 7.1% during the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after purchasing an additional 15,997 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in Abivax in the 3rd quarter worth about $5,217,000. Voya Investment Management LLC acquired a new stake in Abivax in the 3rd quarter worth about $978,000. Quadrature Capital Ltd purchased a new stake in Abivax during the 2nd quarter worth approximately $148,000. Finally, Saturn V Capital Management LP raised its holdings in shares of Abivax by 12.6% during the second quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock valued at $4,762,000 after acquiring an additional 69,553 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.